Organelle-specific Hsp90 inhibitors

[1]  M. Amiji,et al.  Mitochondrial biology, targets, and drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Y. Seo.  Small Molecule Inhibitors to Disrupt Protein-protein Interactions of Heat Shock Protein 90 Chaperone Machinery , 2015, Journal of cancer prevention.

[3]  W. Ying,et al.  An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein , 2014, Cancers.

[4]  Y. Seo,et al.  Synthesis of Flavokawain Analogues and their Anti-neoplastic Effects on Drug-resistant Cancer Cells Through Hsp90 Inhibition , 2014 .

[5]  M. Hance,et al.  Extracellular Hsp90 mediates an NF‐κB dependent inflammatory stromal program: Implications for the prostate tumor microenvironment , 2014, The Prostate.

[6]  D. Proia,et al.  Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. , 2014, Cancer research.

[7]  B. Blagg,et al.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. , 2014, Bioorganic & medicinal chemistry.

[8]  Katerina Sidera,et al.  HSP90 inhibitors: current development and potential in cancer therapy. , 2014, Recent patents on anti-cancer drug discovery.

[9]  Y. Seo,et al.  Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). , 2014, Bioorganic & medicinal chemistry letters.

[10]  Y. Seo,et al.  Targeting the hydrophobic region of Hsp90's ATP binding pocket with novel 1,3,5-triazines. , 2013, Bioorganic & medicinal chemistry letters.

[11]  Y. Seo.  Discovery of Licochalcone A as a Natural Product Inhibitor of Hsp90 and Its Effect on Gefitinib Resistance in Non-Small Cell Lung Cancer (NSCLC) , 2013 .

[12]  Kate S. Carroll,et al.  Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. , 2012, The Journal of nutritional biochemistry.

[13]  M. Hance,et al.  Secreted Hsp90 Is a Novel Regulator of the Epithelial to Mesenchymal Transition (EMT) in Prostate Cancer* , 2012, The Journal of Biological Chemistry.

[14]  M. Meyerson,et al.  Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[15]  L. Rajendran,et al.  Lipid-anchored drugs for delivery into subcellular compartments. , 2012, Trends in pharmacological sciences.

[16]  Wei Li,et al.  Secreted heat shock protein-90 (Hsp90) in wound healing and cancer. , 2012, Biochimica et biophysica acta.

[17]  L. Regan,et al.  A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. , 2011, Molecular pharmaceutics.

[18]  F. Sotgia,et al.  Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? , 2011, BMC medicine.

[19]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[20]  Neal Rosen,et al.  Targeted cancer therapies , 2011, Chinese journal of cancer.

[21]  Thomas Becker,et al.  Common ground for protein translocation: access control for mitochondria and chloroplasts , 2011, Nature Reviews Molecular Cell Biology.

[22]  E. Solary,et al.  Transactivation of the Epidermal Growth Factor Receptor by Heat Shock Protein 90 via Toll-like Receptor 4 Contributes to the Migration of Glioblastoma Cells* , 2010, The Journal of Biological Chemistry.

[23]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[24]  R. Slack,et al.  Reactive oxygen species: stuck in the middle of neurodegeneration. , 2010, Journal of Alzheimer's disease : JAD.

[25]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[26]  F. Esposito,et al.  Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. , 2010, Gynecologic oncology.

[27]  I. Leav,et al.  Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. , 2010, The American journal of pathology.

[28]  D. Stellas,et al.  Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits , 2010, BMC Cell Biology.

[29]  D. Chan,et al.  Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation , 2010, BMC Cancer.

[30]  Hubing Shi,et al.  The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy , 2009, Proceedings of the National Academy of Sciences.

[31]  D. Altieri,et al.  COMPARTMENTALIZED CANCER DRUG DISCOVERY TARGETING MITOCHONDRIAL Hsp90 CHAPERONES , 2009, Oncogene.

[32]  F. Esposito,et al.  TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. , 2009, Cancer letters.

[33]  G. Bu,et al.  Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90α autocrine signaling to promote keratinocyte migration , 2009, Journal of Cell Science.

[34]  K. Bhalla,et al.  Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.

[35]  L. Neckers,et al.  Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. , 2009, The Journal of clinical investigation.

[36]  Fang Yi,et al.  A novel class of small molecule inhibitors of Hsp90. , 2008, ACS chemical biology.

[37]  Dean Billheimer,et al.  Prostate cancer serum biomarker discovery through proteomic analysis of alpha‐2 macroglobulin protein complexes , 2008, Proteomics. Clinical applications.

[38]  Yingdong Zhao,et al.  Journal of Translational Medicine Transcriptional Patterns, Biomarkers and Pathways Characterizing Nasopharyngeal Carcinoma of Southern China , 2008 .

[39]  J. Reinstein,et al.  The ATPase Cycle of the Mitochondrial Hsp90 Analog Trap1* , 2008, Journal of Biological Chemistry.

[40]  L. Neckers,et al.  A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion , 2008, Oncogene.

[41]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[42]  M. Gaitanou,et al.  A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2* , 2008, Journal of Biological Chemistry.

[43]  Tao Zhang,et al.  A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells , 2008, Molecular Cancer Therapeutics.

[44]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[45]  D. Altieri,et al.  Regulation of Tumor Cell Mitochondrial Homeostasis by an Organelle-Specific Hsp90 Chaperone Network , 2007, Cell.

[46]  L. Neckers,et al.  Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis , 2007, Cancer science.

[47]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[48]  Emmanouil D Karagiannis,et al.  Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. , 2006, Journal of theoretical biology.

[49]  Bin Chen,et al.  The HSP90 family of genes in the human genome: insights into their divergence and evolution. , 2005, Genomics.

[50]  K. Yamada,et al.  Dual function of focal adhesion kinase in regulating integrin‐induced MMP‐2 and MMP‐9 release by human T lymphoid cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[52]  P. Bernardi,et al.  Properties of the Permeability Transition Pore in Mitochondria Devoid of Cyclophilin D* , 2005, Journal of Biological Chemistry.

[53]  Jeffrey Robbins,et al.  Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death , 2005, Nature.

[54]  Tetsuya Watanabe,et al.  Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death , 2005, Nature.

[55]  Y. Masuda,et al.  Involvement of Tumor Necrosis Factor Receptor-associated Protein 1 (TRAP1) in Apoptosis Induced by β-Hydroxyisovalerylshikonin* , 2004, Journal of Biological Chemistry.

[56]  L. Neckers,et al.  Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness , 2004, Nature Cell Biology.

[57]  P. Csermely,et al.  Hsp90 isoforms: functions, expression and clinical importance , 2004, FEBS letters.

[58]  W. Stolz,et al.  Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.

[59]  D. Donner,et al.  The hsp90-related Protein TRAP1 Is a Mitochondrial Protein with Distinct Functional Properties* , 2000, The Journal of Biological Chemistry.

[60]  L. Neckers,et al.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.

[61]  Y. Chen,et al.  A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock , 1996, Molecular and cellular biology.

[62]  Yuan Zhang,et al.  Identification of a Protein with Homology to hsp90 That Binds the Type 1 Tumor Necrosis Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[63]  W. A. Sexton,et al.  STRUCTURE—ACTIVITY RELATIONSHIPS , 1958, The Journal of pharmacy and pharmacology.